Jordi Rodón

Also affiliated with The University of Texas MD Anderson Cancer Center, Vall d'Hebron Institut de Recerca

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

(2023)10.1158/1078-0432.c.6532743

Top 100%

0DataRank

Top 100%0 citations

Roberto Carmagnani Pestana, Jason Roszik, David S. Hong, Aung Naing, Siqing Fu +18 more

Papers

Driven by 34 papers — median percentile 0. Top paper: “Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials”.

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Nature Medicine(2023)10.1038/s41591-022-02103-8

N/A

4.3DataRank · unranked

388 citations

Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Funda Meric‐Bernstam +44 more

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Breast Cancer Research(2020)10.1186/s13058-020-01354-y

N/A

3.0DataRank · unranked

148 citations

Cristina Saura, Romualdo Barroso‐Sousa, Hao Guo, Eva Ciruelos, Begoña Bermejo +18 more

Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification

Journal of Clinical Oncology(2022)10.1200/jco.22.00830

N/A

2.2DataRank · unranked

97 citations

Shuyang Yao, Yuan Yuan, Rebecca A. Previs, Anthony Elias, Richard D. Carvajal +15 more

The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial

Investigational New Drugs(2021)10.1007/s10637-020-01043-9

N/A

1.1DataRank · unranked

25 citations

Amir A. Jazaeri, Shannon N. Westin, Anil K. Sood, Lois M. Ramondetta, Mingxuan Xu +8 more

National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities

The Lancet Oncology(2023)10.1016/s1470-2045(23)00297-8

N/A

1.1DataRank · unranked

39 citations

Minesh P. Mehta, Dee Dee Smart, Patricia S. Steeg, Julie A. Hong, Michael Graham Espey +39 more

Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma

Journal of Hepatology(2023)10.1016/j.jhep.2023.10.041

N/A

1.0DataRank · unranked

36 citations

Ming Zhao, Kurt W. Evans, Kaushik Varadarajan, Tyler Moss, Stephen Scott +12 more

Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

Cancer Research Communications(2023)10.1158/2767-9764.crc-22-0260

N/A

0.943DataRank · unranked

37 citations

Niamh Coleman, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, Filip Jankú, Jordi Rodón +13 more

Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3629

N/A

0.719DataRank · unranked

21 citations

Justin T. Moyers, Jason Roszik, Shiraj Sen, David S. Hong, Aung Naing +29 more

Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial

Nature Medicine(2024)10.1038/s41591-024-02934-7

N/A

0.637DataRank · unranked

69 citations

Silvia Damian, Muhammad Furqan, Jesús García-Donás, Hiroo Imai, Antoîne Italiano +10 more

Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology

npj Precision Oncology(2022)10.1038/s41698-022-00317-0

N/A

0.607DataRank · unranked

17 citations

Siqing Fu, David S. Hong, Daniel D. Karp, Sarina A. Piha‐Paul, Vivek Subbiah +18 more

A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors

The Oncologist(2023)10.1093/oncolo/oyad158

N/A

0.438DataRank · unranked

10 citations

Apostolia M. Tsimberidou, Xueyao Fu, Siqing Fu, Vivek Subbiah, Anil K. Sood +7 more

Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial

Scientific Reports(2022)10.1038/s41598-022-16588-3

N/A

0.375DataRank · unranked

4 citations

David S. Hong, Christine B. Peterson, Bettzy Stephen, Ecaterina E. Dumbrava, Shubbam Pant +18 more

Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1703

N/A

0.373DataRank · unranked

11 citations

Richard K. Yang, Alexander J. Lazar, Shalin S. Patel, Valerae O. Lewis, Jason Roszik +13 more

Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2509

N/A

0.345DataRank · unranked

9 citations

Roberto Carmagnani Pestana, Jason Roszik, David S. Hong, Aung Naing, Siqing Fu +18 more

Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi -NT in Patients with Advanced Solid Tumors

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3952

N/A

0.330DataRank · unranked

8 citations

Filip Jankú, Siqing Fu, Ecaterina E. Dumbrava, David S. Hong, Daniel D. Karp +20 more

Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies

npj Precision Oncology(2023)10.1038/s41698-023-00369-w

N/A

0.312DataRank · unranked

7 citations

Roman Groisberg, Ralph Zinner, Andrew W. Hahn, Aung Naing, Shizhen Zhang +16 more

Targeting Oxidative Phosphorylation with a Mitochondrial Complex I Inhibitor is limited by Mechanism-based Toxicity

Research Square(2022)10.21203/rs.3.rs-1506700/v1

N/A

0.269DataRank · unranked

5 citations

Timothy A. Yap, Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka +43 more

First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma: A Case Report

JCO Precision Oncology(2024)10.1200/po.23.00633

N/A

0.254DataRank · unranked

3 citations

Eduardo Andreazza Dal Lago, Juliana Mota Siqueira, Luana Guimarães de Sousa, Adel K. El‐Naggar, Jordi Rodón +2 more

Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations

ESMO Open(2025)10.1016/j.esmoop.2025.104136

N/A

0.241DataRank · unranked

4 citations

Chieh Tseng, Hai T. Tran, Aung Naing, Ecaterina E. Dumbrava, DD Karp +9 more

Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial

Journal of Immunotherapy and Precision Oncology(2025)10.36401/jipo-24-17

N/A

0.217DataRank · unranked

3 citations

Mohamed A. Gouda, Matthew J. Reilley, Amadeo B. Biter, JoAnn Lim, Stacie A. Bean +15 more

A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma

Cancer Medicine(2025)10.1002/cam4.70280

N/A

0.212DataRank · unranked

3 citations

Mohamed A. Gouda, Denái R. Milton, Hassan Ahmed Momin, Bülent Yılmaz, Bettzy Stephen +16 more

532 A phase 1 dose escalation and dose expansion trial of NP-101 in patients with advanced solid tumors

Regular and Young Investigator Award Abstracts(2025)10.1136/jitc-2025-sitc2025.0532

N/A

0DataRank · unranked

0 citations

Bettzy Stephen, Serdar A. Gurses, Michelle York Gocio, Mohamed Omar Kaseb, Yali Yang +18 more

584 Phase I/II study to evaluate the safety and tolerability of avelumab in combination with other anti-cancer therapies in patients with advanced malignancies

Regular and Young Investigator Award Abstracts(2023)10.1136/jitc-2023-sitc2023.0584

N/A

0DataRank · unranked

0 citations

Anne Knisely, Bettzy Stephen, Yali Yang, Juhee Song, Anas Alshawa +9 more

Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer

Research Square(2022)10.21203/rs.3.rs-2248209/v1

N/A

0DataRank · unranked

0 citations

Turçin Saridogan, Argun Akçakanat, Ming Zhao, Kurt W. Evans, Erkan Yuca +11 more

Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer

Journal of Immunotherapy and Precision Oncology(2023)10.36401/jipo-22-23

N/A

0DataRank · unranked

1 citations

Heather Lin, Siqing Fu, Amadeo B. Biter, Ecaterina E. Dumbrava, Daniel D. Karp +15 more

Data from Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer

(2023)10.1158/1078-0432.c.6528374.v1

N/A

0DataRank · unranked

0 citations

Amber M. Johnson, Ecaterina E. Dumbrava, Kanwal Raghav, Kavitha Balaji, Michelle Bhatt +4 more

Data from Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

(2023)10.1158/1078-0432.c.6532743

Top 100%

0DataRank

Top 100%0 citations

Roberto Carmagnani Pestana, Jason Roszik, David S. Hong, Aung Naing, Siqing Fu +18 more

Data from Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

(2023)10.1158/1078-0432.c.6532743.v1

Top 100%

0DataRank

Top 100%0 citations

Roberto Carmagnani Pestana, Jason Roszik, David S. Hong, Aung Naing, Siqing Fu +18 more

HER2-low expression in patients with advanced or metastatic solid tumors

Annals of Oncology(2023)10.1016/j.annonc.2023.08.005

N/A

0DataRank · unranked

72 citations

Cara Haymaker, Gabriela Raso, Serena Masciari, Lei Wang, Heather Lin +20 more

First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors

The Oncologist(2024)10.1093/oncolo/oyad338

N/A

0DataRank · unranked

27 citations

Binghe Xu, Ecaterina E. Dumbrava, Siqing Fu, Daniel D. Karp, Funda Meric‐Bernstam +20 more

Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts

Cancer Discovery(2024)10.1158/2159-8290.cd-23-0838

N/A

0DataRank · unranked

25 citations

Kurt W. Evans, Bailiang Wang, Ming Zhao, Argun Akçakanat, Maria Gabriela Raso +14 more

Metastatic extraneural glioblastoma diagnosed with molecular testing

The Oncologist(2024)10.1093/oncolo/oyae115

N/A

0DataRank · unranked

1 citations

Henry Hiep Vo, César A. Moran, Shiao‐Pei Weathers, I-Wen Song, Garret Williford +4 more

Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1233

N/A

0DataRank · unranked

1 citations

Kurt W. Evans, Stephen Scott, Xiaofeng Zheng, Kaushik Varadarajan, Lawrence N. Kwong +16 more

Exceptional response to the ATR inhibitor, camonsertib, in a patient with ALT+ metastatic melanoma

npj Precision Oncology(2025)10.1038/s41698-025-01025-1

N/A

0DataRank · unranked

3 citations

Ian M. Silverman, Adrienne Johnson, Chenfeng Meng, Joseph D. Schonhoft, Michal Zimmermann +10 more

Jordi Rodón

Indexed papers

Top data-sharing exemplar

Papers